Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic

Drug Metabolism and Disposition

Volumn 40, Issue 9, 2012, Pages 1677-1685

  Wang, Haiqing ^a   Wang, Lifei ^a   Cao, Kai ^a   Emanuel, Stuart L ^a   Morin, Paul ^a   Lin, Zheng ^a   Shen, Guoxiang ^a   Hosbach, Jennifer ^a   Zhang, Donglu ^a   Bonacorsi, Samuel ^a   Rodrigues, A David ^a   Yang, Zheng ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CARBON 14; CYSTEINE; MACROGOL; MALEIMIDE; PEGDINETANIB; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL ACTIVITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; TUMOR XENOGRAFT; WHOLE BODY AUTORADIOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTORADIOGRAPHY; BIOLOGICAL AGENTS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; FEMALE; FIBRONECTINS; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; ISOTOPE LABELING; MICE; MICE, NUDE; MUTATION; NEOPLASMS; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; TUMOR BURDEN; WHOLE BODY IMAGING;

EID: 84865168363     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.044792     Document Type: Article

References (27)

1. Alagic A, Koprianiuk A, and Kluger R (2005) Hemoglobin-superoxide dismutase-chemical linkages that create a dual-function protein. J Am Chem Soc 127:8036-8043. (Pubitemid 40799657)
2. Bailon P and Won CY (2009) PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6:1-16.
3. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34:850-858.
4. Chakrabarti MC, Le N, Paik CH, De Graff WG, and Carrasquillo JA (1996) Prevention of radiolysis of monoclonal antibody during labeling. J Nucl Med 37:1384-1388. (Pubitemid 26330679)
5. Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, et al. (2008) Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 73:338-348. (Pubitemid 351159204)
6. Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, et al. (2011) A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 3:38-48.
7. Fishburn CS (2008) The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 97:4167-4183.
8. Gaberc-Porekar V, Zore I, Podobnik B, and Menart V (2008) Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 11:242-250. (Pubitemid 351281064)
9. Gay RD, Clarke AW, Elgundi Z, Domagala T, Simpson RJ, Le NB, Doyle AG, and Jennings PA (2010) Anti-TNFα domain antibody construct CEP-37247: full antibody functionality at half the size. MAbs 2:625-638.
10. Gebauer M and Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255.
11. Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J, and Boerman OC (2011) Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer 129:870-878.
12. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Müller D, and Kontermann RE (2010) The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 23:827-834.
13. Hovgaard D, Mortensen BT, Schifter S, and Nissen NI (1992) Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur J Clin Invest 22:45-49.
14. Hovgaard DJ, Folke M, Mortensen BT, and Nissen NI (1994) Recombinant human interleukin-3: pharmacokinetics after intravenous and subcutaneous bolus injection and effects on granulocyte kinetics. Br J Haematol 87:700-707. (Pubitemid 24264639)
15. Ishida T and Kiwada H (2008) Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354:56-62.
16. Jevsevar S, Kunstelj M, and Porekar VG (2010) PEGylation of therapeutic proteins. Biotechnol J 5:113-128.
17. Lipovsek D (2011) Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 24:3-9.
18. 86Y for quantitative PET of carcinoma. J Nucl Med 51:942-950.
19. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, and Brechbiel MW (2010b) PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 37:1368-1376.
20. Niu G, Li Z, Xie J, Le QT, and Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50:1116-1123.
21. Sato H (2002) Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 54:487-504.
22. Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295-304.
23. Stork R, Campigna E, Robert B, Müller D, and Kontermann RE (2009) Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 284:25612-25619.
24. Taguchi T (1986) Clinical studies of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 57:1705-1708.
25. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, et al. (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363-371.
26. 111In-DOTA-Z EGFR: 2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 37:613-622.
27. Veronese FM and Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs 22:315-329.